13588-1-AP
antibody from Proteintech Group
Targeting: GZMB
CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT
Antibody data
- Antibody Data
- Antigen structure
- References [29]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13588-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#13588-1-AP, RRID:AB_2114429
- Product name
- Granzyme B antibody
- Antibody type
- Polyclonal
- Description
- Granzyme B antibody (Cat. #13588-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: FC, IF, IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments.
Tumorous IRE1α facilitates CD8(+)T cells-dependent anti-tumor immunity and improves immunotherapy efficacy in melanoma.
Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer.
Induction of Tumor Ferroptosis-Dependent Immunity via an Injectable Attractive Pickering Emulsion Gel.
Exploring the molecular mechanisms of the involvement of GZMB-Caspase-3-GSDME pathway in the progression of rheumatoid arthritis.
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate.
A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Single-cell transcriptomics reveals intestinal cell heterogeneity and identifies Ep300 as a potential therapeutic target in mice with acute liver failure.
Schisandrin B induces HepG2 cells pyroptosis by activating NK cells mediated anti-tumor immunity.
Exploring the effect of polyamines on NK cell function in colorectal cancer process based on glycolysis.
Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety.
Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy.
B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
The Role of Tim-3 on dNK Cells Dysfunction During Abnormal Pregnancy With Toxoplasma gondii Infection.
Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice.
In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE).
Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
VEGF165b augments NK92 cytolytic activity against human K562 leukemia cells by upregulating the levels of perforin and granzyme B via the VEGR1-PLC pathway.
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Granzyme B is recovered by natural killer cells via clathrin-dependent endocytosis.
Chen T, Deng J, Zhang Y, Liu B, Liu R, Zhu Y, Zhou M, Lin Y, Xia B, Lin K, Ma X, Zhang H
Molecular cancer 2024 Mar 11;23(1):53
Molecular cancer 2024 Mar 11;23(1):53
Tumorous IRE1α facilitates CD8(+)T cells-dependent anti-tumor immunity and improves immunotherapy efficacy in melanoma.
Yang Y, Wang S, Wang XX, Guo S, Wang H, Shi Q, Tian Y, Wang H, Zhao T, Zhang H, Zhang B, Gao T, Li C, Yi X, Guo W
Cell communication and signaling : CCS 2024 Jan 30;22(1):83
Cell communication and signaling : CCS 2024 Jan 30;22(1):83
Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
Wang H, Zhou Z, Zhang J, Hao T, Wang P, Wu P, Su R, Yang H, Deng G, Chen S, Gu L, He Y, Zeng L, Zhang C, Yin S
Cancer letters 2024 Jan 28;581:216498
Cancer letters 2024 Jan 28;581:216498
Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
Zhang Q, Yang C, Ma Z, Ye L, Wu Y, Zhong C, Shi Y, Zhu M
Molecular carcinogenesis 2024 Aug;63(8):1611-1620
Molecular carcinogenesis 2024 Aug;63(8):1611-1620
The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
Lu Y, Sun Y, Zhang J, Kong M, Zhao Z, Sun B, Wang Y, Jiang Y, Chen S, Wang C, Tong Y, Wen L, Huang M, Wu F, Zhang L
Cancer letters 2024 Aug 1;596:217020
Cancer letters 2024 Aug 1;596:217020
The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer.
Ge W, Meng L, Cao S, Hou C, Zhu X, Huang D, Li Q, Peng Y, Jiang K
Journal of immunology research 2023;2023:6891636
Journal of immunology research 2023;2023:6891636
Induction of Tumor Ferroptosis-Dependent Immunity via an Injectable Attractive Pickering Emulsion Gel.
Dai X, Zhang J, Bao X, Guo Y, Jin Y, Yang C, Zhang H, Liu L, Gao Y, Ye C, Wu W, Liu C, Zhao CX, Sheng J, Ren E, Li H, Fang W, Wu B, Ruan J, Gu Z, Chen D, Zhao P
Advanced materials (Deerfield Beach, Fla.) 2023 Sep;35(35):e2303542
Advanced materials (Deerfield Beach, Fla.) 2023 Sep;35(35):e2303542
Exploring the molecular mechanisms of the involvement of GZMB-Caspase-3-GSDME pathway in the progression of rheumatoid arthritis.
Zhang Y, Cai X, Wang B, Zhang B, Xu Y
Molecular immunology 2023 Sep;161:82-90
Molecular immunology 2023 Sep;161:82-90
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate.
Xu T, Dai J, Tang L, Sun L, Si L, Guo J
Cancer immunology, immunotherapy : CII 2023 Nov;72(11):3491-3505
Cancer immunology, immunotherapy : CII 2023 Nov;72(11):3491-3505
A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J, Zhang M, Tian Q, Yang J
Clinical and experimental medicine 2023 Nov;23(7):3867-3881
Clinical and experimental medicine 2023 Nov;23(7):3867-3881
Single-cell transcriptomics reveals intestinal cell heterogeneity and identifies Ep300 as a potential therapeutic target in mice with acute liver failure.
Yin J, Zhao Z, Huang J, Xiao Y, Rehmutulla M, Zhang B, Zhang Z, Xiang M, Tong Q, Zhang Y
Cell discovery 2023 Jul 25;9(1):77
Cell discovery 2023 Jul 25;9(1):77
Schisandrin B induces HepG2 cells pyroptosis by activating NK cells mediated anti-tumor immunity.
Song A, Ding T, Wei N, Yang J, Ma M, Zheng S, Jin H
Toxicology and applied pharmacology 2023 Aug 1;472:116574
Toxicology and applied pharmacology 2023 Aug 1;472:116574
Exploring the effect of polyamines on NK cell function in colorectal cancer process based on glycolysis.
He H, Song Z, Lin S, Wang Y, Wang G
International immunopharmacology 2023 Apr;117:109944
International immunopharmacology 2023 Apr;117:109944
Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety.
Liu C, Li L, Gao F, Zhou J, Qin Y, Yuan X, Yang G, Zhu Y
Frontiers in bioengineering and biotechnology 2022;10:928169
Frontiers in bioengineering and biotechnology 2022;10:928169
Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy.
Guo H, Zhang W, Wang L, Shao Z, Huang X
Biomaterials 2022 Nov;290:121821
Biomaterials 2022 Nov;290:121821
B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
Lu Y, Wu F, Cao Q, Sun Y, Huang M, Xiao J, Zhou B, Zhang L
Oncogene 2022 Jan;41(5):704-717
Oncogene 2022 Jan;41(5):704-717
EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
Xu T, Dai J, Tang L, Yang L, Si L, Sheng X, Cui C, Chi Z, Kong Y, Guo J
The Journal of investigative dermatology 2022 Apr;142(4):1158-1170.e8
The Journal of investigative dermatology 2022 Apr;142(4):1158-1170.e8
The Role of Tim-3 on dNK Cells Dysfunction During Abnormal Pregnancy With Toxoplasma gondii Infection.
Li T, Cui L, Xu X, Zhang H, Jiang Y, Ren L, Yang C, Liu X, Hu X
Frontiers in cellular and infection microbiology 2021;11:587150
Frontiers in cellular and infection microbiology 2021;11:587150
Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
Yuan Q, Liang Q, Sun Z, Yuan X, Hou W, Wang Y, Wang H, Yu M
Oncoimmunology 2021;10(1):1914954
Oncoimmunology 2021;10(1):1914954
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
Zhang L, Wang X, Li Y, Han J, Gao X, Li S, Wang F
Clinical and translational medicine 2021 Sep;11(9):e464
Clinical and translational medicine 2021 Sep;11(9):e464
Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice.
Xu L, Cai P, Li X, Wu X, Gao J, Liu W, Yang J, Xu Q, Guo W, Gu Y
Toxicology and applied pharmacology 2021 Oct 1;428:115672
Toxicology and applied pharmacology 2021 Oct 1;428:115672
In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE).
Wei PS, Chen YJ, Lin SY, Chuang KH, Sheu MT, Ho HO
Biomaterials 2021 Nov;278:121166
Biomaterials 2021 Nov;278:121166
Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Zhang J, Wang L, Xu X, Li X, Guan W, Meng T, Xu G
Frontiers in oncology 2020;10:1787
Frontiers in oncology 2020;10:1787
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Cai X, Wei B, Li L, Chen X, Liu W, Cui J, Lin Y, Sun Y, Xu Q, Guo W, Gu Y
International immunopharmacology 2020 Nov;88:106858
International immunopharmacology 2020 Nov;88:106858
VEGF165b augments NK92 cytolytic activity against human K562 leukemia cells by upregulating the levels of perforin and granzyme B via the VEGR1-PLC pathway.
Wang X, Liang C, Xia W, Guo C, Niu Z, Zhu W, Zhang H
Molecular immunology 2020 Dec;128:41-46
Molecular immunology 2020 Dec;128:41-46
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, Pu K, Zhu Y
Cancer immunology research 2018 Feb;6(2):178-188
Cancer immunology research 2018 Feb;6(2):178-188
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W
Journal of hematology & oncology 2018 Feb 6;11(1):16
Journal of hematology & oncology 2018 Feb 6;11(1):16
Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, Chu CY
Journal of the American Academy of Dermatology 2014 Mar;70(3):539-48
Journal of the American Academy of Dermatology 2014 Mar;70(3):539-48
Granzyme B is recovered by natural killer cells via clathrin-dependent endocytosis.
Li P, Zheng G, Yang Y, Zhang C, Xiong P, Xu Y, Fang M, Tan Z, Zheng F, Gong F
Cellular and molecular life sciences : CMLS 2010 Sep;67(18):3197-208
Cellular and molecular life sciences : CMLS 2010 Sep;67(18):3197-208
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HL-60 cells were subjected to SDS PAGE followed by western blot with 13588-1-AP(GZMB antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Hela cells, using GZMB antibody 13588-1-AP at 1:50 dilution and Rhodamine-labeled goat anti-rabbit IgG (red). Blue pseudocolor = DAPI (fluorescent DNA dye).
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human lymphoma using 13588-1-AP(GZMB antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human lymphoma using 13588-1-AP(GZMB antibody) at dilution of 1:100 (under 40x lens)
- Sample type
- tissue